Non-Invasive Prenatal Testing Market Report by Product Type (Consumables, Instruments), Test Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY, and Others), Technology (NGS, WGS, and Others), Method (Ultrasound Detection, Biochemical Screening Tests, Cell-Free DNA in Maternal Plasma Tests, Fetal Cells in Maternal Blood Tests, and Others), Application (Trisomy, Microdeletion Syndrome, and Others), End-User (Hospitals, Diagnostic Laboratories, and Others), and Region 2024-2032
The global non-invasive prenatal testing market size reached US$ 4.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 14.0 Billion by 2032, exhibiting a growth rate (CAGR) of 14.6% during 2024-2032.
Non-invasive prenatal testing (NIPT) is a form of prenatal screening conducted on a pregnant woman’s blood sample to detect the presence of fetal abnormalities. The test is primarily used to diagnose genetic disorders such as Down syndrome (or trisomy 21), Edwards syndrome (or trisomy 18), Patau syndrome (or trisomy 13) and Turner syndrome, by analyzing DNA fragments in the mother’s blood. The procedure eliminates the need for various precarious and invasive procedures, such as chorionic villus sampling (CVS) and can be performed after nine weeks of pregnancy.
The growing prevalence of genetic disorders of the fetus is one of the key factors driving the market growth. Furthermore, technological advancements in the field of life sciences and healthcare industry is also providing a boost to the market. For instance, the development of DNA sequencing technologies, regenerative medicines and breakthroughs in molecular research have created immense possibilities to combat the chances of any serious disease at the primitive stage itself. Additionally, the increasing acceptance rate for prenatal testing, along with rising health consciousness and awareness regarding the benefits and significance of such testing among the masses, is also driving the market growth. Healthcare providers, as well as expecting parents, are adopting alternatives to diagnose other genetic disorders, including spina bifida, cleft palate, and sickle cell anemia, and treat them in the early stages of fetal development. Moreover, the shifting trend toward childbearing at high maternal age (35 years or older) is also positively impacting the market growth. Advancing maternal age can lead to numerous health complications, such as high blood pressure, reduced fertility, risk of miscarriage and increased risk of chromosomal anomalies in the fetus.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global non-invasive prenatal testing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, test type, technology, method, application and end-user.
Breakup by Product Type:
Consumables
Instruments
Breakup by Test Type:
Materni 21
Harmony
Panaroma
Verifi
NIFTY
Others
Breakup by Technology:
NGS
WGS
Others
Breakup by Method:
Ultrasound Detection
Biochemical Screening Tests
Cell-Free DNA in Maternal Plasma Tests
Fetal Cells in Maternal Blood Tests
Others
Breakup by Application:
Trisomy
Microdeletion Syndrome
Others
Breakup by End-User:
Hospitals
Diagnostic Laboratories
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the top non invasive prenatal testing companies key players being Agilent Technologies, Inc., Berry Genetics, Inc., BGI Genomics Co., Ltd., Eurofins Scientific Services Limited, F. Hoffmann-La Roche Ltd, GE Healthcare, Igenomix, Illumina Inc., Laboratory Corporation, Natera Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc., and Yourgene Health plc.
Key Questions Answered in This Report
1. What was the size of the global non-invasive prenatal testing market in 2023?
2. What is the expected growth rate of the global non-invasive prenatal testing market during 2024-2032?
3. What are the key factors driving the global non-invasive prenatal testing market?
4. What has been the impact of COVID-19 on the global non-invasive prenatal testing market?
5. What is the breakup of the global non-invasive prenatal testing market based on the product type?
6. What is the breakup of the global non-invasive prenatal testing market based on the test type?
7. What is the breakup of the global non-invasive prenatal testing market based on the technology?
8. What is the breakup of the global non-invasive prenatal testing market based on the method?
9. What is the breakup of the global non-invasive prenatal testing market based on the application?
10. What is the breakup of the global non-invasive prenatal testing market based on the end-user?
11. What are the key regions in the global non-invasive prenatal testing market?
12. Who are the key companies/players in the global non-invasive prenatal testing market?
Non-invasive prenatal testing (NIPT) is a form of prenatal screening conducted on a pregnant woman’s blood sample to detect the presence of fetal abnormalities. The test is primarily used to diagnose genetic disorders such as Down syndrome (or trisomy 21), Edwards syndrome (or trisomy 18), Patau syndrome (or trisomy 13) and Turner syndrome, by analyzing DNA fragments in the mother’s blood. The procedure eliminates the need for various precarious and invasive procedures, such as chorionic villus sampling (CVS) and can be performed after nine weeks of pregnancy.
The growing prevalence of genetic disorders of the fetus is one of the key factors driving the market growth. Furthermore, technological advancements in the field of life sciences and healthcare industry is also providing a boost to the market. For instance, the development of DNA sequencing technologies, regenerative medicines and breakthroughs in molecular research have created immense possibilities to combat the chances of any serious disease at the primitive stage itself. Additionally, the increasing acceptance rate for prenatal testing, along with rising health consciousness and awareness regarding the benefits and significance of such testing among the masses, is also driving the market growth. Healthcare providers, as well as expecting parents, are adopting alternatives to diagnose other genetic disorders, including spina bifida, cleft palate, and sickle cell anemia, and treat them in the early stages of fetal development. Moreover, the shifting trend toward childbearing at high maternal age (35 years or older) is also positively impacting the market growth. Advancing maternal age can lead to numerous health complications, such as high blood pressure, reduced fertility, risk of miscarriage and increased risk of chromosomal anomalies in the fetus.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global non-invasive prenatal testing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, test type, technology, method, application and end-user.
Breakup by Product Type:
Consumables
Instruments
Breakup by Test Type:
Materni 21
Harmony
Panaroma
Verifi
NIFTY
Others
Breakup by Technology:
NGS
WGS
Others
Breakup by Method:
Ultrasound Detection
Biochemical Screening Tests
Cell-Free DNA in Maternal Plasma Tests
Fetal Cells in Maternal Blood Tests
Others
Breakup by Application:
Trisomy
Microdeletion Syndrome
Others
Breakup by End-User:
Hospitals
Diagnostic Laboratories
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the top non invasive prenatal testing companies key players being Agilent Technologies, Inc., Berry Genetics, Inc., BGI Genomics Co., Ltd., Eurofins Scientific Services Limited, F. Hoffmann-La Roche Ltd, GE Healthcare, Igenomix, Illumina Inc., Laboratory Corporation, Natera Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc., and Yourgene Health plc.
Key Questions Answered in This Report
1. What was the size of the global non-invasive prenatal testing market in 2023?
2. What is the expected growth rate of the global non-invasive prenatal testing market during 2024-2032?
3. What are the key factors driving the global non-invasive prenatal testing market?
4. What has been the impact of COVID-19 on the global non-invasive prenatal testing market?
5. What is the breakup of the global non-invasive prenatal testing market based on the product type?
6. What is the breakup of the global non-invasive prenatal testing market based on the test type?
7. What is the breakup of the global non-invasive prenatal testing market based on the technology?
8. What is the breakup of the global non-invasive prenatal testing market based on the method?
9. What is the breakup of the global non-invasive prenatal testing market based on the application?
10. What is the breakup of the global non-invasive prenatal testing market based on the end-user?
11. What are the key regions in the global non-invasive prenatal testing market?
12. Who are the key companies/players in the global non-invasive prenatal testing market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY PRODUCT TYPE
6.1 Consumables
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Instruments
6.2.1 Market Trends
6.2.2 Market Forecast
7 MARKET BREAKUP BY TEST TYPE
7.1 Materni
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Harmony
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Panaroma
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Verifi
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 NIFTY
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Others
7.6.1 Market Trends
7.6.2 Market Forecast
8 MARKET BREAKUP BY TECHNOLOGY
8.1 NGS
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 WGS
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast
9 MARKET BREAKUP BY METHOD
9.1 Ultrasound Detection
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Biochemical Screening Tests
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Cell-Free DNA in Maternal Plasma Tests
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Fetal Cells in Maternal Blood Tests
9.4.1 Market Trends
9.4.2 Market Forecast
9.5 Others
9.5.1 Market Trends
9.5.2 Market Forecast
10 MARKET BREAKUP BY APPLICATION
10.1 Trisomy
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Microdeletion Syndrome
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Others
10.3.1 Market Trends
10.3.2 Market Forecast
11 MARKET BREAKUP BY END-USER
11.1 Hospitals
11.1.1 Market Trends
11.1.2 Market Forecast
11.2 Diagnostic Laboratories
11.2.1 Market Trends
11.2.2 Market Forecast
11.3 Others
11.3.1 Market Trends
11.3.2 Market Forecast
12 MARKET BREAKUP BY REGION
12.1 North America
12.1.1 United States
12.1.1.1 Market Trends
12.1.1.2 Market Forecast
12.1.2 Canada
12.1.2.1 Market Trends
12.1.2.2 Market Forecast
12.2 Asia Pacific
12.2.1 China
12.2.1.1 Market Trends
12.2.1.2 Market Forecast
12.2.2 Japan
12.2.2.1 Market Trends
12.2.2.2 Market Forecast
12.2.3 India
12.2.3.1 Market Trends
12.2.3.2 Market Forecast
12.2.4 South Korea
12.2.4.1 Market Trends
12.2.4.2 Market Forecast
12.2.5 Australia
12.2.5.1 Market Trends
12.2.5.2 Market Forecast
12.2.6 Indonesia
12.2.6.1 Market Trends
12.2.6.2 Market Forecast
12.2.7 Others
12.2.7.1 Market Trends
12.2.7.2 Market Forecast
12.3 Europe
12.3.1 Germany
12.3.1.1 Market Trends
12.3.1.2 Market Forecast
12.3.2 France
12.3.2.1 Market Trends
12.3.2.2 Market Forecast
12.3.3 United Kingdom
12.3.3.1 Market Trends
12.3.3.2 Market Forecast
12.3.4 Italy
12.3.4.1 Market Trends
12.3.4.2 Market Forecast
12.3.5 Spain
12.3.5.1 Market Trends
12.3.5.2 Market Forecast
12.3.6 Russia
12.3.6.1 Market Trends
12.3.6.2 Market Forecast
12.3.7 Others
12.3.7.1 Market Trends
12.3.7.2 Market Forecast
12.4 Latin America
12.4.1 Brazil
12.4.1.1 Market Trends
12.4.1.2 Market Forecast
12.4.2 Mexico
12.4.2.1 Market Trends
12.4.2.2 Market Forecast
12.4.3 Others
12.4.3.1 Market Trends
12.4.3.2 Market Forecast
12.5 Middle East and Africa
12.5.1 Market Trends
12.5.2 Market Breakup by Country
12.5.3 Market Forecast
13 SWOT ANALYSIS
13.1 Overview
13.2 Strengths
13.3 Weaknesses
13.4 Opportunities
13.5 Threats
14 VALUE CHAIN ANALYSIS
15 PORTERS FIVE FORCES ANALYSIS
15.1 Overview
15.2 Bargaining Power of Buyers
15.3 Bargaining Power of Suppliers
15.4 Degree of Competition
15.5 Threat of New Entrants
15.6 Threat of Substitutes
16 COMPETITIVE LANDSCAPE
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 Agilent Technologies, Inc.
16.3.1.1 Company Overview
16.3.1.2 Product Portfolio
16.3.1.3 Financials
16.3.1.4 SWOT Analysis
16.3.2 Berry Genetics Inc.
16.3.2.1 Company Overview
16.3.2.2 Product Portfolio
16.3.3 BGI Genomics Co. Ltd.
16.3.3.1 Company Overview
16.3.3.2 Product Portfolio
16.3.3.3 Financials
16.3.4 Eurofins Scientific Services Limited
16.3.4.1 Company Overview
16.3.4.2 Product Portfolio
16.3.4.3 Financials
16.3.5 F. Hoffmann-La Roche Ltd
16.3.5.1 Company Overview
16.3.5.2 Product Portfolio
16.3.5.3 SWOT Analysis
16.3.6 GE Healthcare
16.3.6.1 Company Overview
16.3.6.2 Product Portfolio
16.3.7 Igenomix
16.3.7.1 Company. Overview
16.3.7.2 Product Portfolio
16.3.7.3 Financials
16.3.8 Illumina Inc.
16.3.8.1 Company Overview
16.3.8.2 Product Portfolio
16.3.8.3 Financials
16.3.8.4 SWOT Analysis
16.3.9 Laboratory Corporation
16.3.9.1 Company Overview
16.3.9.2 Product Portfolio
16.3.9.3 Financials
16.3.9.4 SWOT Analysis
16.3.10 Natera Inc.
16.3.10.1 Company Overview
16.3.10.2 Product Portfolio
16.3.10.3 Financials
16.3.11 Perkinelmer Inc.
16.3.11.1 Company Overview
16.3.11.2 Product Portfolio
16.3.11.3 Financials
16.3.11.4 SWOT Analysis
16.3.12 Thermo Fisher Scientific Inc.
16.3.12.1 Company Overview
16.3.12.2 Product Portfolio
16.3.12.3 Financials
16.3.12.4 SWOT Analysis
16.3.13 Yourgene Health plc
16.3.13.1 Company Overview
16.3.13.2 Product Portfolio
16.3.13.3 Financials
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY PRODUCT TYPE
6.1 Consumables
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Instruments
6.2.1 Market Trends
6.2.2 Market Forecast
7 MARKET BREAKUP BY TEST TYPE
7.1 Materni
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Harmony
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Panaroma
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Verifi
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 NIFTY
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Others
7.6.1 Market Trends
7.6.2 Market Forecast
8 MARKET BREAKUP BY TECHNOLOGY
8.1 NGS
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 WGS
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast
9 MARKET BREAKUP BY METHOD
9.1 Ultrasound Detection
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Biochemical Screening Tests
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Cell-Free DNA in Maternal Plasma Tests
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Fetal Cells in Maternal Blood Tests
9.4.1 Market Trends
9.4.2 Market Forecast
9.5 Others
9.5.1 Market Trends
9.5.2 Market Forecast
10 MARKET BREAKUP BY APPLICATION
10.1 Trisomy
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Microdeletion Syndrome
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Others
10.3.1 Market Trends
10.3.2 Market Forecast
11 MARKET BREAKUP BY END-USER
11.1 Hospitals
11.1.1 Market Trends
11.1.2 Market Forecast
11.2 Diagnostic Laboratories
11.2.1 Market Trends
11.2.2 Market Forecast
11.3 Others
11.3.1 Market Trends
11.3.2 Market Forecast
12 MARKET BREAKUP BY REGION
12.1 North America
12.1.1 United States
12.1.1.1 Market Trends
12.1.1.2 Market Forecast
12.1.2 Canada
12.1.2.1 Market Trends
12.1.2.2 Market Forecast
12.2 Asia Pacific
12.2.1 China
12.2.1.1 Market Trends
12.2.1.2 Market Forecast
12.2.2 Japan
12.2.2.1 Market Trends
12.2.2.2 Market Forecast
12.2.3 India
12.2.3.1 Market Trends
12.2.3.2 Market Forecast
12.2.4 South Korea
12.2.4.1 Market Trends
12.2.4.2 Market Forecast
12.2.5 Australia
12.2.5.1 Market Trends
12.2.5.2 Market Forecast
12.2.6 Indonesia
12.2.6.1 Market Trends
12.2.6.2 Market Forecast
12.2.7 Others
12.2.7.1 Market Trends
12.2.7.2 Market Forecast
12.3 Europe
12.3.1 Germany
12.3.1.1 Market Trends
12.3.1.2 Market Forecast
12.3.2 France
12.3.2.1 Market Trends
12.3.2.2 Market Forecast
12.3.3 United Kingdom
12.3.3.1 Market Trends
12.3.3.2 Market Forecast
12.3.4 Italy
12.3.4.1 Market Trends
12.3.4.2 Market Forecast
12.3.5 Spain
12.3.5.1 Market Trends
12.3.5.2 Market Forecast
12.3.6 Russia
12.3.6.1 Market Trends
12.3.6.2 Market Forecast
12.3.7 Others
12.3.7.1 Market Trends
12.3.7.2 Market Forecast
12.4 Latin America
12.4.1 Brazil
12.4.1.1 Market Trends
12.4.1.2 Market Forecast
12.4.2 Mexico
12.4.2.1 Market Trends
12.4.2.2 Market Forecast
12.4.3 Others
12.4.3.1 Market Trends
12.4.3.2 Market Forecast
12.5 Middle East and Africa
12.5.1 Market Trends
12.5.2 Market Breakup by Country
12.5.3 Market Forecast
13 SWOT ANALYSIS
13.1 Overview
13.2 Strengths
13.3 Weaknesses
13.4 Opportunities
13.5 Threats
14 VALUE CHAIN ANALYSIS
15 PORTERS FIVE FORCES ANALYSIS
15.1 Overview
15.2 Bargaining Power of Buyers
15.3 Bargaining Power of Suppliers
15.4 Degree of Competition
15.5 Threat of New Entrants
15.6 Threat of Substitutes
16 COMPETITIVE LANDSCAPE
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 Agilent Technologies, Inc.
16.3.1.1 Company Overview
16.3.1.2 Product Portfolio
16.3.1.3 Financials
16.3.1.4 SWOT Analysis
16.3.2 Berry Genetics Inc.
16.3.2.1 Company Overview
16.3.2.2 Product Portfolio
16.3.3 BGI Genomics Co. Ltd.
16.3.3.1 Company Overview
16.3.3.2 Product Portfolio
16.3.3.3 Financials
16.3.4 Eurofins Scientific Services Limited
16.3.4.1 Company Overview
16.3.4.2 Product Portfolio
16.3.4.3 Financials
16.3.5 F. Hoffmann-La Roche Ltd
16.3.5.1 Company Overview
16.3.5.2 Product Portfolio
16.3.5.3 SWOT Analysis
16.3.6 GE Healthcare
16.3.6.1 Company Overview
16.3.6.2 Product Portfolio
16.3.7 Igenomix
16.3.7.1 Company. Overview
16.3.7.2 Product Portfolio
16.3.7.3 Financials
16.3.8 Illumina Inc.
16.3.8.1 Company Overview
16.3.8.2 Product Portfolio
16.3.8.3 Financials
16.3.8.4 SWOT Analysis
16.3.9 Laboratory Corporation
16.3.9.1 Company Overview
16.3.9.2 Product Portfolio
16.3.9.3 Financials
16.3.9.4 SWOT Analysis
16.3.10 Natera Inc.
16.3.10.1 Company Overview
16.3.10.2 Product Portfolio
16.3.10.3 Financials
16.3.11 Perkinelmer Inc.
16.3.11.1 Company Overview
16.3.11.2 Product Portfolio
16.3.11.3 Financials
16.3.11.4 SWOT Analysis
16.3.12 Thermo Fisher Scientific Inc.
16.3.12.1 Company Overview
16.3.12.2 Product Portfolio
16.3.12.3 Financials
16.3.12.4 SWOT Analysis
16.3.13 Yourgene Health plc
16.3.13.1 Company Overview
16.3.13.2 Product Portfolio
16.3.13.3 Financials
